Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
St Pharm Co. Ltd. currently faces 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is handled by 1 distinct examiner, MAHADEVAN, JANAKI ANANTH, who is the busiest examiner for the company with 1 pending office action. The prosecution is confined to 1 distinct art unit.
The presence of 1 pending office action indicates a low volume of active prosecution for the company. Because there is only 1 distinct examiner and 1 distinct art unit, the company's interactions with the USPTO are centralized. MAHADEVAN, JANAKI ANANTH is the only examiner currently reviewing the company's biotech innovations.
The concentration of the workload under a single examiner suggests a streamlined prosecution process. Because there is only 1 busiest examiner pending action, the technical focus of the examination remains narrow. Practitioners working with MAHADEVAN, JANAKI ANANTH will find that this individual manages the entirety of the company's currently pending work. This structure allows for a very specific legal strategy tailored to the preferences of a single examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MAHADEVAN, JANAKI ANANTH | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18032511 | OLIGONUCLEOTIDE FOR 5'-CAPPED RNA SYNTHESIS | MAHADEVAN, JANAKI ANANTH | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18032511 | OLIGONUCLEOTIDE FOR 5'-CAPPED RNA SYNTHESIS | MAHADEVAN, JANAKI ANANTH | 1681 | §103 | Non-Final OA | — | Pending | Apr 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSt Pharm Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Janaki Ananth Mahadevan has the most, with 1 of St Pharm Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
